SOLAR-PROMOTION
28.5.2024 10:42:32 CEST | Business Wire | Press release
Visitors to The smarter E Europe, Europe’s Largest Alliance of Exhibitions for the Energy Industry, will find out how private consumers can become self-sufficient in electricity, heat and transport in a smart way and how this creates new business opportunities for installers and system providers. The smarter E Europe combines the four trade fairs Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power Europe and takes place from June 19 to 21 at Messe München. Around 3,000 exhibitors and more than 115,000 visitors from all over the world are expected in 19 exhibition halls and on an outdoor area.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528827105/en/
The smarter E Europe shows interplay of components. ©Solar Promotion GmbH
There are around 19.3 million residential buildings in Germany. More than half of these will need to be renovated and equipped with photovoltaics over the next 20 years. But residential buildings also play a central role in solar expansion throughout Europe. Everywhere, solar systems are being installed with storage systems, as this allows the solar power generated to be used as needed.
Increasing electrification in the transport and heating sectors
Solar power has been generated and stored to supply the home, but what else can it be used for? For the increasingly popular electric car. In the home system, battery electric vehicles as well as heat pumps can be charged and operated cost-effectively and climate-neutrally with the solar power. In Germany, 51 percent more heat pumps were sold last year than in 2022. With the adoption of the EU Heat Pump Action Plan, this development will continue dynamically. The combination of PV, a storage system, electric car and heat pump forms an effective network of electricity-generating, electricity-storing and electricity-consuming units.
An interplay of components and trade disciplines
The industry offers a wide range of components - from PV systems and intelligent wall boxes to smart meters and much more. However, successfully building a comprehensive energy system requires not only interaction between the individual components, but also smooth cooperation between the electrical trade, plumbing, heating and air conditioning technology (HVAC) and other trades.
Optimize self-consumption, relieve the grid
The electricity system requires a high degree of flexibility in order to be able to provide a renewable energy supply 24/7. Flexible small consumers with their own home energy systems can make a major contribution to keeping electricity generation and consumption in balance while optimizing their own consumption at low cost.
Dynamic electricity tariffs: Supply meets demand
Dynamic electricity tariffs are another way of better coordinating supply and demand. Consumers base their consumption on the current electricity prices, which change depending on supply and demand. From 2025, all electricity suppliers in Germany will be obliged to offer their customers a dynamic electricity tariff. Prerequisite for this is the installation of a smart meter.
The smarter E Europe
"Accelerating Integrated Energy Solutions" - under this motto, The smarter E Europe, Europe's largest trade fair alliance for the energy industry, focuses on cross-industry solutions for a 24/7 renewable energy supply in the electricity, heating and transport sectors. The smarter E Europe combines four trade fairs and will take place from June 19-21, 2024 at Messe München.
Further information: www.TheSmarterE.de
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528827105/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom